Last Updated:

TPG eyes on 7% Stake In PharmEasy

US-based private firm TPG is expecting to gain a 7% stake in e-pharmacy startup PharmEasy and has examined for antitrust watchdog Competition Commission of India's (CCI) permission for the following.

The governing filings highlight that TPG will help out the stated speculation through its unusual design vehicle in Singapore. “API Holdings will use this financing to deepen its distribution network across India and build innovative technology-first products to connect the entire ecosystem and give affordable access to healthcare across India,” the filing read.

Despite the fact that the documenting didn't reveal some extra value-based elegances, a past media report had tapped that TPG will put $100 Mn in the health-tech startup beside media combination Naspers. The report notified that Pharmaeasy will be considered at a unicorn estimate of $1.2 Bn for this round. The TPG was first declared by ET.

The increase comes two months after PharmEasy got CCI's endorsement on its consolidation with competitor Medlife. The agreement will see PharmEasy’s parent organisation API Holdings getting 100% equity shares in Medlife, whereas Medlife’s promoters will in return get a 19.95% stake in the merged entity.

Founded in 2015 by Sheth and Dr Dhaval Shah, PharmEasy provides to the continuous care segment and allows a variety of services such as teleconsultation, medicine distributions, and sample collections for diagnostic examinations. The company also possesses a subscription-based service. The company has branded its presence in more than 1000 cities.

It has so far boosted $328 Mn over seven funding series from investors like Temasek, Bessemer Venture Partners, and Nandan Nilekani, amid others. The company lately declared a $3 Mn ESOP buyback plan, which will profit 40-45 employees.

PharmEasy is presently attempting to stay aware of the changing nature of the e-pharmacy section. In the course of the most recent couple of months, undertakings like Amazon and Reliance Retail have officially entered the boosting segment. While Amazon dispatched its own pharmacy portion, Reliance gained startup Netmeds for $83 Mn.

Indeed, even Flipkart and Tata Group are hoping to make a gateway into the industry. Flipkart has just begun selling once over-the-counter items and is supposed to be in talks with different new companies for partnership. Reports propose that Tata will get 1mg, which secured the top place in the segment before the entry of enterprises.